• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$6.80 -$0.01 (-0.15%)

REAL-TIME: Last trade at

THRESHOLD PHARMACEUTICALS, INC...

NASDAQ:THLD

Jump to this page for:

Related Resources

Threshold Pharmaceuticals remains undervalued, says Cowen

5/25/2012 by Theflyonthewall.com

Hitting The Jackpot With Small Cap Bio Pharma Investment, Part 2: A Threshold Investment

5/16/2012 by Seeking Alpha

6 Best Biotech Stocks With More Upside Potential

5/7/2012 by Seeking Alpha

Threshold Pharmaceuticals reports Q1 EPS ($2.30), consensus 14c

5/3/2012 by Theflyonthewall.com

Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs

4/25/2012 by StockWatch

Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs

4/25/2012 by Marketwire

5 Stocks Under $10 Poised for Gains

4/13/2012 by TheStreet.com

2 Attractive Biotech Stocks, With Good Entry Points

4/13/2012 by Seeking Alpha

Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference

4/13/2012 by StockWatch

Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference

4/13/2012 by Marketwire

Threshold Pharmaceuticals Earns $20M Milestone Payment From Merck KGaA For Positive Results From Phase 2 Trial Of TH-302 In Pancreatic Cancer

4/12/2012 by Pharmaceutical Online

Threshold Pharma Gets $20M from Merck KGaA After Phase II Success with Anticancer Agent

4/11/2012 by Genetic Engineering News

Threshold Pharmaceuticals earns $20M milestone payment from Merck KGaA

4/11/2012 by Theflyonthewall.com

Threshold Pharmaceuticals Earns $20 Million Milestone Payment From Merck KGaA for Positive Results From Phase 2 Trial of TH-302 in Pancreatic Cancer

4/11/2012 by Marketwire

Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm

4/5/2012 by TheStreet.com

Bullish Brokerage Note Propels Threshold Pharmaceuticals' Call Volume

4/3/2012 by Schaeffer's Daily Market Blog

Bullish Brokerage Note Propels Threshold Pharmaceuticals' Call Volume

4/3/2012 by Schaeffer's Investment Research

Lazard Capital to host a bus tour

4/3/2012 by Theflyonthewall.com

Mizuho Securities Starts Threshold Pharmaceuticals (THLD) at Buy

4/2/2012 by StreetInsider.com

Threshold Pharmaceuticals Announces Detailed Results From Positive Phase 2b Trial of TH-302 in Pancreatic Cancer at AACR Annual Meeting

3/30/2012 by Genetic Engineering News

Threshold Pharmaceuticals (THLD) Reports Positive Phase 2b Trial of TH-302 in Pancreatic Cancer

3/30/2012 by StreetInsider.com

Threshold Pharmaceuticals Announces Detailed Results From Positive Phase 2b Trial of TH-302 in Pancreatic Cancer at AACR Annual Meeting

3/30/2012 by Marketwire

Threshold Pharmaceuticals, Inc.'s Cancer Drug Gets FDA Orphan Status, Shares Rise

3/30/2012 by BioSpace

Pre-market Movers For March 30 (RIMM, THLD, IMGN, XRTX, SHPGY, DNKN, FINL)

3/30/2012 by RTTNews

Threshold Pharmaceuticals Receives Orphan Drug Designation for TH-302 for the Treatment of Soft Tissue Sarcoma

3/30/2012 by Pharmaceutical Processing

UPDATE: Threshold Pharma (THLD) Receives Orphan Drug Status for TH-302 for the Treatment of Soft Tissue Sarcoma

3/30/2012 by StreetInsider.com

Threshold Pharma receives US Orphan Drug Designation for TH-302

3/30/2012 by Theflyonthewall.com

Threshold Pharmaceuticals Receives US Orphan Drug Designation for TH-302 for the Treatment of Soft Tissue Sarcoma

3/30/2012 by Marketwire

UPDATE: Threshold Pharmaceuticals (THLD) Higher After Lazard Capital More Than Doubles Price Target

3/29/2012 by StreetInsider.com

Threshold Pharma price target raised to $15 from $7 at Lazard Capital

3/29/2012 by Theflyonthewall.com

Threshold Pharma to host conference call

3/28/2012 by Theflyonthewall.com

The Dow Dazzles — Monday’s IP Market Recap

3/26/2012 by InvestorPlace

Threshold Pharma falls 2.7%

3/26/2012 by Theflyonthewall.com

Lightning Round: Threshold Pharmaceuticals, Medco Health Solutions, Tempur-Pedic and More

3/19/2012 by CNBC

'Mad Money Lightning Round: Freeport McMoRan Will Surprise

3/19/2012 by TheStreet.com

JMP Securities Boosts Target on Threshold Pharmaceuticals (THLD), Sees 72% Upside

3/19/2012 by StreetInsider.com

Threshold Pharma target raised to $12 from $7 at JMP Securities

3/19/2012 by Theflyonthewall.com

Threshold Pharma (THLD): TH-302 Drug To Treat Soft Tissue Sarcoma Gets Orphan Drug Designation

3/16/2012 by iStockAnalyst

Another Boost For Threshold (THLD)

3/16/2012 by 24/7 Wall Street

Threshold Pharma's TH-302 receives orphan drug designation in EU

3/16/2012 by Theflyonthewall.com
See More Articles...